Speed Medical results, Q2 2024
Net profit, assets, equity and cash flow for Q2 2024, against the same period a year earlier, from the published financial statements.
Net profit-21.51 millionEGP · +13.4% vs the same period a year earlier
Total assets548 millionEGP · −3.2% vs the same period a year earlier
Shareholders' equity258 millionEGP · +11.3% vs the same period a year earlier
Operating cash flow517 thousandEGP · −94.1% vs the same period a year earlier
In short
- Speed Medical's net profit for Q2 2024 was about -21.51 million EGP, up +13.4% from -24.82 million EGP in Q2 2023.
- Total assets at the end of Q2 2024 were about 548 million EGP, and shareholders' equity about 258 million EGP.
- Operating cash flow for Q2 2024 was positive at 517 thousand EGP.
Key lines against the same period a year earlier
This periodQ2 2023Change
Net profit-21.51 million-24.82 million+13.4%
Gross profit-4.78 million-1.82 million−163.2%
Total assets548 million566 million−3.2%
Total liabilities289 million333 million−13.3%
Shareholders' equity258 million232 million+11.3%
Total liabilities and equity548 million566 million−3.2%
Operating cash flow517 thousand8.72 million−94.1%
Investing cash flow-13.63 million-1.79 million−660.1%
Financing cash flow8.48 million-7.55 million+212.3%
Net change in cash-4.64 million-621 thousand−648.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Speed Medical's Q2 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy